Bruchertseifer, Frank

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding

Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Diagnosis and Treatment

Cited by 505

Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study

Sathekge, M. M., Lawal, I. O., Bal, C., Bruchertseifer, F., Ballal, S., Cardaci, G., Davis, C., Eiber, M., Hekimsoy, T., Knoesen, O., et al. (2024) · The Lancet Oncology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 210

DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.

Graf, F., Fahrer, J., Maus, S., Morgenstern, A., Bruchertseifer, F., Venkatachalam, S., Fottner, C., Weber, M. M., Huelsenbeck, J., Schreckenberger, M., et al. (2014) · PLoS ONE

Radiopharmaceutical Chemistry and ApplicationsNeuroendocrine Tumor Research Advances

Cited by 143

Supply and clinical application of Actinium-225 and Bismuth-213.

Morgenstern, A., Apostolidis, C., & Bruchertseifer, F. (2020) · Seminars in Nuclear Medicine

Radiopharmaceutical Chemistry and ApplicationsChemical Reactions and Isotopes

Cited by 141

An Improved Method for the Production of Ac-225/Bi-213 from Th-229 for Targeted Alpha Therapy.

Zielinska, B., Apostolidis, C., Bruchertseifer, F., & Morgenstern, A. (2007) · Solvent Extraction and Ion Exchange

Radiopharmaceutical Chemistry and ApplicationsRadioactive element chemistry and processing

Cited by 100

mCRPC Patients Receiving 225 Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis

Sathekge, M., Bruchertseifer, F., Vorster, M., Lawal, I. O., Knoesen, O., Mahapane, J., Davis, C., Mdlophane, A., Maes, A., Mokoala, K., et al. (2022) · Journal of Nuclear Medicine

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 81

Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC

Hooijman, E. L., Chalashkan, Y., Ling, S. W., Kahyargil, F. F., Segbers, M., Bruchertseifer, F., Morgenstern, A., Seimbille, Y., Koolen, S. L. W., Brabander, T., et al. (2021) · Pharmaceutics

Radiopharmaceutical Chemistry and ApplicationsChemical Reactions and Isotopes

Cited by 59

Targeted alpha therapy with 213Bi.

Morgenstern, A., Bruchertseifer, F., & Apostolidis, C. (2011) · Current Radiopharmaceuticalse

Radiopharmaceutical Chemistry and ApplicationsRadioactivity and Radon Measurements

Cited by 58